BOZEMAN, Mont. (July 23, 2009) – Golden Helix, Inc., a global leader in genetic analysis software and services, today announced a transition program to assist research institutions impacted by Microsoft’s recent acquisition of Rosetta Biosoftware. Under the terms of the program, Golden Helix will provide special pricing, services, and support to help Syllego users evaluate a transition to a new platform.
On June 1st, Microsoft signed an agreement to acquire Rosetta Biosoftware, a unit of Rosetta Inpharmatics, from its parent company, Merck. The transaction was completed on June 26th. Shortly thereafter, Microsoft announced that Rosetta Biosoftware’s three products, Resolver, Syllego, and Elucidator, would no longer be sold and that support would likewise end in 2011.
Golden Helix’s transition program focuses on users of Rosetta’s Syllego system, a software package for genome-wide association studies. According to Christophe Lambert, president and CEO of Golden Helix, and co-chair of the FDA’s MAQC CNV Data Analysis Team, “Rosetta’s users find themselves at an unexpected crossroads. We have deep expertise and several solutions for genome-wide studies, including best-in-class CNV and interaction analysis tools, which enable us to provide helpful information for Syllego users, whether they choose our platform or not.”
Golden Helix’s SNP & Variation Suite (SVS) is a collection of innovative software tools for SNP and CNV association studies, for both population and family-based research, wrapped in an intuitive graphical interface. It is a modular package, allowing researchers to acquire only the functionality needed, and includes an interactive genome browser plus extensive visualization and advanced analysis tools to facilitate exploration.
Lambert continued, “Unfortunately, Rosetta customers are faced with a decision: continue using Rosetta software for a while and then transition, or do so now – in either case a transition will be necessary; the Golden Helix program makes that transition easier.”
About Golden Helix
Founded in 1998, Golden Helix has become the global leader in SNP and copy number analysis, genetic association software, and analysis services. Using industry-leading technologies, Golden Helix provides a comprehensive suite of software tools that empower the genetic research community, enabling them to determine the genetic causes of disease, transform drug discovery, create genetic diagnostics, and advance the quest for personalized medicine. Used by hundreds of researchers at the world's top pharmaceutical, biotech, and academic research organizations, the company’s products have been cited in over 150 peer-reviewed publications that detail groundbreaking research uncovering the genetic and environmental basis of disease. Learn more at www.goldenhelix.com.
Josh Forsythe, Director of Marketing
Golden Helix, Inc.